Please try another search
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops TAB008 for the treatment of non-squamous non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, fallopian tube cancer, or primary peritoneal cancer, and hepatocellular carcinoma. It also offers TOZ309 for the treatment of glioblastoma multiforme or anaplastic astrocytoma. In addition, the company develops TAA013 for HER2+ breast cancer; TAE020 which is under preclinical trial for acute myeloid leukemia; and TAB014 for wet age-related macular degeneration. Further it develops TAC020 for the treatment various solid tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Shan Fu | 52 | 2016 | Chairman of the Board |
Jun Liu | 53 | 2018 | CEO, Chief Scientific Officer & Executive Director |
Chun-Ying Yeh-Huang | 64 | 2016 | Non-Executive Vice Chairman of the Board |
Lan Hu | 51 | 2019 | Independent Non-Executive Director |
Hong-Jen Chang | 66 | 2019 | Independent Non-Executive Director |
De Qian Wang | 72 | 2022 | Independent Non-Executive Director |
Weidong Liu | 55 | 2023 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review